… , eptifibatide, and abciximab) are approved for clinical use in patients affected by percutaneous
coronary interventions (PCI) in … undergoing primary PCI was related to decreased median …

… While abciximab does not require any dose adjustment, … ml/min/1.73 m 2 and eptifibatide
requires a reduction in the infusion … will still have systemic anti-platelet effects that may increase …

… , the null effect with respect to ex vivo thrombus area that we … Variability in thrombus area
was lower than originally … : results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (…

… potent anti-platelet agents and anticoagulants to reduce … /IIIa inhibitors including abciximab,
eptifibatide and tirofiban … [18] for PCI are associated with a significant decrease in peri-…

… Abciximab, eptifibatide and tirofiban are indicated as adjuncts to PCI for the prevention of …
and osteoporosis, the risks of both in which LMWHs are lower than unfractionated heparin. …

… and subsEquent Dual Anti Platelet Therapy),[6] and the PARIS (Patterns of non-Adherence
to … (GPI) abciximab, tirofiban, and eptifibatide have all been shown to reduce the incidence of …

… strategy for anti-platelet therapy during PCI in the recent future. … Abciximab, tirofiban and
eptifibatide are intravenous GP IIb/… primary PCI, non-fatal MI at 30 days was reduced with use of …

… are the GPIs (abciximab [ReoPro], eptifibatide [Integrilin], … can be potentially reduced with
shorter postPCI infusions, bolus-… ACC/AHA versus ESC guidelines on dual antiplatelet therapy: …

… that has shown the benefits of eptifibatide use in PCI was … choice for these patients and was
even preferred over abciximab [98]. … ICH was reduced after the administration of eptifibatide. …

… GPIs (abciximab, tirofiban and eptifibatide) inhibit the final … options for primary PCI include
UFH (unfractionated heparin), … at 60 min post-PCI and reduced distal embolization and no …